The Use of Platelet-Rich Plasma in Osteoarthritis and Fractures

In order to promote and enhance bone healing, biologic drugs have been studied and used recently. Plasmon rich plasma, or PRP, is one of these substances that is becoming more and more popular as an emerging tactic. Examining the available research on PRP injection use and clinical efficacy—particularly with regard to treating non-union fractures—is the primary goal of this study. Recent Discoveries Even though level IV evidence predominated, most published research claimed that PRP sped up the healing of fractures. Currently impeding the successful clinical translation of platelet-rich plasma (PRP) as a therapy for non-union fractures is the absence of randomized, clinical trials (level I–II evidence). Its ability to cure non-union fractures, either on its own or in conjunction with other therapies, has been reported to be promising. Entire text The effects of delivering larger volumes of PRP (i.e., 5–20 mL) and the necessity of longer (> 11 months) randomised clinical trials are two future recommendations that should help accelerate clinical translation and adoption of PRP as a therapeutic.minimum negative consequences.